QoL of Colorectal Cancer Patients and Spouses
Ontology highlight
ABSTRACT:
DISEASE(S): Stoma Colostomy,Rectum Cancer,Rectal Neoplasms,Stoma Ileostomy,Sigmoid Cancer,Sigmoid Neoplasms
PROVIDER: 2366620 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Primary outcome(s): The rate of improvement of QOL using SF-36 healthy questionnaire
| 2635476 | ecrin-mdr-crc
Project description:<p>STARNET is a genetics of RNA expression study of multiple disease-relevant tissues obtained from living patients with cardiovascular disease. Tissue samples are obtained from blood, atherosclerotic-lesion-free internal mammary artery (MAM) and atherosclerotic aortic root (AOR), subcutaneous fat (SF), visceral abdominal fat (VAF), skeletal muscle (SKLM), and liver (LIV) during open thorax surgery of 600 coronary artery disease (CAD) patients. All patients gave written informed consent. The inclusion criterion was eligibility for coronary artery by-pass graft (CABG) surgery. Patients with other severe systemic diseases, such as active systemic inflammatory disease or cancer, were excluded. The primary clinical end points were the SYNTAX score based on the extent of coronary atherosclerosis assessed from preoperative angiograms. The STARNET patients are Caucasians (31% females); 32% had diabetes, 75% had hypertension, and 67% had hyperlipidemia; and 33% had an MI before age 60. By New York Heart Association criteria, 45% were class I, 42% class II, 9% class III, and 1% class IV. </p> <p>TYPES AND RNA SEQUENCING: 566 DNA genotype and 3577 RNA-seq profiles from seven tissues from 600 STARNET CABG patients passed quality control (on average 511 RNA-seq profiles/tissue). DNA was genotyped with the OmniExpress Exome array (Illumina, ~900k SNPs) and imputed to a total of 14,098,063 DNA variant calls (6,245,505 with minor allele frequency >5%). The STARNET subjects mainly overlap with Caucasian of Northern European (Finnish) descent. RNA sequencing was performed using the HighSeq2000 platform, poly-A (LIV, SKLM, VAF, SF and blood) and ribo-zero (AOR, MAM) protocols with 50-100 bp read lengths, single end to 15-30 million read depth. </p>
| phs001203 | dbGaP
Project description:This is a randomized, double-blind parallel-group, placebo-controlled study. that will last 40 weeks and will focus on Quality of Life.36 Subjects with stage IV metastatic colorectal cancer will be referred for study inclusion. Patients will be randomly assigned (1:1 ratio) to take 2 ml of LentinexHP or placebo orally twice a day (a total of 6 mg). Products will be dispensed to allow administration of the product for six weeks. Each bottle of LentinexHP or placebo contains 30 mL, which at 1.5 mg/mL will provide dosage for approximately five days. The patients will periodically complete the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Quality of Life (QoL) instrument, the short form 36 (SF-36), the Fatigue Symptom Inventory (FSI), and the QoL questionnaire used in the previous LentinexHP QoL study.
| 67164 | ecrin-mdr-crc
Project description:Identification of specific risk groups for recurrence after surgery for colorectal liver metastases (CRLM) remains challenging due to the heterogeneity of the disease. Classical clinicopathologic parameters have limited prognostic and predictive value. The aim of this study was to identify a gene expression signature measured in CRLM discriminating early from late recurrence after surgery for CRLM. Methods: Tumour samples of CRLM from two patient groups were collected: I) patients with recurrent disease within 12 months after surgery (N=33), and II) patients without recurrences and disease free for at least 36 months (N=30). The included patients were clinically homogeneous; all patients had a low risk profile (clinical risk score 0-2) and did not receive (neo-) adjuvant chemotherapy. Extracted total RNA from both groups was hybridized to Illumina arrays, and processed for analysis. A leave-one-out cross validation (LOOCV) analysis was performed to identify a potentially prognostic gene expression signature. Results: The LOOCV yielded an 11-gene profile with prognostic value in relation to recurrent disease within 12 months after partial hepatectomy. This gene expression profile had a sensitivity of 81.8%, with a specificity of 66.7% for predicting early recurrences (within 12 months) versus no recurrences for at least 36 months after surgery (X2 P<0.0001). Conclusion: The current study yielded an 11-gene signature at mRNA level in CRLM discriminating early from late or no relapse after partial hepatectomy.
2017-01-01 | GSE81423 | GEO
Project description:To investigate whether the gene expression profiles of synovial fluid mesenchymal stem cells (SF-MSCs) from rat OA knees were favorable for endogenous cartilage repair, we performed RNA sequencing for SF-MSCs from intact knees and knees 4 weeks after the pMx and sham surgery.
2023-08-17 | GSE227922 | GEO
Project description:Various forms of chronic arthritis like osteoarthritis (OA) or rheumatoid arthritis (RA) are major causes of disability and represent a global burden on health care systems. Inter- and intraindividual differences in the phenotype of arthritis often prevent early diagnosis and effective treatment. Previously, we suggested that site-specific differences in the joint stroma influence the development and the outcome of arthritis and showed that the long non-coding RNA HOTAIR is expressed exclusively in synovial fibroblasts (SF) of lower joints. Here, we further analysed the function of HOTAIR in SF and in arthritis development. We show that joint-specific HOTAIR expression in SF is stronlgy imprinted in the chromatin landscape of SF by epigenetic mechanisms. Nevertheless, HOTAIR expression in knee SF was downregulated by inflammatory cytokines. Accordingly, HOTAIR was more expressed in OA tissues than in RA tissues. Downregulation of HOTAIR regulated relevant arthritis pathways by epigenetic and transcriptional mechanisms and modified the migratory function of SF, decreased SF mediated osteoclastogenesis, and increased the attraction of B cells by SF. We propose that HOTAIR downregulation in inflammation epigenetically regulates important pathways and functions in SF, and thus modulates the phenotype of arthritis in lower extremity joints.
2023-01-01 | GSE185440 | GEO
Project description:New early low-invasive biomarkers are demanded for the management of Oligoarticular Juvenile Idiopathic Arthritis (OJIA), the most common chronic inflammatory arthritis in childhood and a leading cause of disability. Extracellular vesicles (EVs) released in the synovial fluid (SF) of inflamed joints have gained increased recognition as mediators of arthritis pathogenesis and as a source of biomarkers. No standardized protocol is available, yet, for the analysis of EV-derived microRNAs (EV-miRs) in human SF specimens, and their potential as biomarkers in OJIA has not been explored. This study proposes an optimized procedure for profiling EV-miRs in SF and represents the first investigation of the miRNome in EV isolated from OJIA patients at disease onset. We present data showing efficient recovery of EVs from SF aspirates and optimal profiling of their miRNA content. We identified a subset of 15 EV-miRs whose expression was deregulated in SF. Analysis of EV-miRs target genes evidenced the enrichemnt of processes related to inflammation, cartilage/bone homeostasis, hypoxia, and hormone metabolism, suggesting their contribution to disease pathogenesis and potential as new putative biomarkers. In addition, we detected altered expression levels of several circulating EV-miRs able to discriminate new-onset OJIA patients from control children. Among them, 16 were consensually overexpressed in both PL and SF from OJIA patients respect to controls, potentially representing a disease-associated molecular “fingerprint” measurable at both the systemic and local levels with high diagnostic potential. These results improve our understanding of OJIA molecular mechanisms and provide an important contribution in the search of new candidate biomarkers for early OJIA diagnosis and the design of novel tailored therapies.
2022-12-30 | GSE191326 | GEO
Project description:New early low-invasive biomarkers are highly demanded for the management of Oligoarticular Juvenile Idiopathic Arthritis (OJIA), the most common chronic pediatric rheumatic disease in Western countries and a leading cause of disability. Despite recent significant advances in OJIA treatment, a high percentage of patients undergo arthritis recurrence and/or extension to other joints by one-two years after onset. A deeper understanding of the molecular basis of OJIA pathophysiology is essential for the identification of biomarkers for early disease detection and patient stratification and to guide targeted therapeutic intervention to allow the development of diagnostic and therapeutic interventions earlier in disease course. Proteomic profiling of extracellular vesicles (EVs) released in biological fluids has recently emerged as a minimally invasive approach to elucidate adult arthritis pathogenic mechanisms and for new biomarker discovery. However, EV-prot expression and potential as biomarkers in OJIA have not been explored. This study represents the first detailed longitudinal characterization investigation of EV proteome in newly diagnosed OJIA patients. Fourty-five OJIA patients were recruited at disease onset and followed up for 24 months, and protein expression profiling was carried out by liquid chromatography-tandem mass spectrometry in EVs isolated from plasma (PL) and synovial fluid (SF) samples. Because joints are the main targets of clinical manifestations, we first searched for EV-prots potentially implicated in disease development by comparing the EV-proteome of SF (SF_OJIA) vs paired PL (PL_OJIA). We identified a subset of 83 proteins significantly (FDR < 0.01) differentially expressed (31 up- and 52 downregulated) in EVs from SF compared to PL and 33 EV-prots exclusively present in SF samples. Pathway analysis revealed EV-prot enrichment in processes related to cartilage/bone metabolism and inflammation suggesting their role in OJIA joint pathogenesis and potential value as early biomarkers of disease development. Comparative analysis of the SF_OJIA and PL_OJIA EV-proteomic profiles was then carried out respect to the PL of 24 age/gender-matched control children (PL_CTR) to identify early disease-specific proteins. Significant up- and down-regulation of 110 and 92 EV-prots, respectively, were observed in PL_OJIA compared to PL_CTR samples, and 294 EV-prots were found exclusively present, effectively differentiating new-onset OJIA patients from control children. EV-prots were significantly associatd to biological processes related to innate immunity, antigen processing and presentation, and cytoskeleton organization. Importantly, a subset of 76 EV-prots displayed consensual regulation in, and 77 exclusively expressed EV-prots were shared by, PL and SF from patients respect to CTR, potentially representing a disease-associated signature measurable at both the systemic and local levels with diagnostic potential. Finally, we runned WGCNA on the SF- and PL-derived EV-prot datasets to search for EV-prot clusters associated to clinical parameters, such as ANA positivity, disease relapse, polyarticular extension, and iridocyclitis development occurring within the 2 years of follow-up, and we identified 9 and 7 EV-prot modules in SF and PL samples, respectively, able to stratify OJIA patients in distinct subgroups with different disease course. These data provide mechanistic insights into OJIA pathophysiology and an important contribution in the search of new candidate biomarkers for the disease.
2023-07-05 | PXD039166 | Pride
Project description:The aim of this study is to identify early pathogenic changes in ileal gene expression that precede the development of macroscopic disease in inflammatory bowel diseases (IBDs). We focused on two IBD phenotypes that were unlikely to overlap: 1) ileal Crohn’s disease (CD) patients undergoing initial ileocolic resection of diseased ileum; and 2) ulcerative colitis (UC) patients undergoing total colectomy. The Control patients were those patients without IBD undergoing initial right hemicolectomy or total colectomy.
2010-09-26 | GSE24287 | GEO
Project description:Background: Sustained sleep insufficiency impairs immune system and increases the adverse outcomes of cardiovascular diseases. However, the role and mechanisms prolonged sleep fragmentation (SF) on the outcomes of myocardial infarction (MI) remains elusive. Methods: Among 497 MI patients with complete sleep data participating in the National Health and Nutrition Examination Survey, the association between different types of sleep disorders and post-MI survivability was evaluated. We then developed a mouse model with 10 weeks of SF followed by MI surgery. Emergency hematopoiesis and neutrophil expansion were analyzed. Potential mechanisms were explored using bone marrow (BM) transplantation, anti-SiglecF neutralizing antibodies and Interferon alpha and beta receptor subunit 1 knockout (Ifnar1-/-) in BM. Results: Frequent nocturnal awakening independently predicted reduced survival rate of MI patients, with a hazard ratio (HR) of 2.136 (95% CI=1.142-3.995). Increased infarct size, deteriorated cardiac function and lower survival rate were also observed in MI mice pretreated with 10-week SF. SF facilitated post-MI neutrophil expansion and infiltration into infarct area, differentiating into SiglecFhi subset. Inhibition of SiglecFhi neutrophils allowed for the alleviations of post-MI cardiac remodeling. Furthermore, BM progenitors were skewed toward neutrophil lineage concomitant with the clonal expansion of granulocyte-monocyte progenitors (GMPs) in MI mice pretreated with 10-week SF. Transcriptome analysis and functional experiments revealed that activation of type I interferon (IFN) signaling was involved in this process, while depletion of Ifnar1 in BM and administration of IFNAR1-neutralizing antibodies significantly alleviated post-MI cardiac remodeling and neutrophil expansion. Conclusions: SF aggravates post-MI cardiac remodeling and dysfunction through promoting GMP differentiation and neutrophil expansion. Blockage of type I IFN could alleviate this detrimental influence.
2024-09-07 | GSE276317 | GEO